Company intelligence / Profile preview
B.A.I. Biosciences
- Ownership
- Private
- Employees
- ~50
- Development stage
- Commercial
Overview
B.A.I. Biosciences has launched commercial skincare products under the Pavise brand using its DiamondCore Shield Technology—a zinc oxide formulation with nano-diamonds to improve UV protection and cosmetic acceptability. The company holds over 20 patents covering novel molecules and technologies targeting dermatological conditions such as atopic dermatitis and skin aging. Early commercial results are promising with projected first-year sales of $20 million for Pavise products[4]. The company also has a robust R&D pipeline focused on both medical and cosmetic dermatology.
- Therapeutic areas
- Dermatology
- Modalities
- Novel small moleculestransdermal drug delivery technologiesnano-diamond enhanced zinc oxide (DiamondCore Shield Technology)
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on B.A.I. Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on B.A.I. Biosciences.